Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today ...
Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted)NEW YORK, ...
The FDA recently granted EXG-34217 Rare Pediatric Disease Designation (RPDD) and Regenerative Medicine Advanced Therapy (RMAT) Designation.
UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an ...
“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...
Researchers have developed a powerful computational tool, named iDOMO, to improve the prediction of drug synergy and accelerate the development of combination therapies for complex diseases. The study ...
Biologists converted gut bacteria into miniature protein factories that manufacture and release a sustained flow of targeted proteins inside the lower intestines. This technique solves one of the ...
Polar Capital Global Healthcare, which is co-managed by James Douglas, currently trades at a 3pc discount to its assets.
UroGen Pharma (NASDAQ:URGN) stock in focus as company acquires oncolytic virus ICVB-1042 from IconOVir Bio, to design ...
Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback